Merck & Co., Inc. and Eisai announce Phase 3 trial results for WELIREG plus LENVIMA in advanced… EP News Bureau Oct 29, 2025 LITESPARK-011 trial meets primary endpoint of progression-free survival in patients previously treated with anti-PD-1/L1 therapy
Long HCC pipeline marks change for previously stagnant market EP News Bureau Nov 3, 2020 Many new therapies entering the market have different mechanisms of action (MOA) and are aiming to meet needs in different…
US FDA declines to approve Merck and Eisai’s liver cancer combo therapy Reuters Jul 9, 2020 The FDA's complete response letter cited lack of sufficient evidence that the Keytruda-Lenvima combination therapy had a…
